124 related articles for article (PubMed ID: 31926585)
1. Network pharmacology-based analysis of mechanisms of the anti-hepatocellular carcinoma effect by dihydroartemisinin.
Liu T; Guo J; Wang T; Zhang S; Yu X; Hou C; Guo D
Discov Med; 2019 Sep; 28(153):139-147. PubMed ID: 31926585
[TBL] [Abstract][Full Text] [Related]
2. TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib.
Hou C; Guo D; Yu X; Wang S; Liu T
Biomed Pharmacother; 2020 Jun; 126():109862. PubMed ID: 32120157
[TBL] [Abstract][Full Text] [Related]
3. Dihydroartemisinin exhibits antitumor activity toward hepatocellular carcinoma in vitro and in vivo.
Zhang CZ; Zhang H; Yun J; Chen GG; Lai PB
Biochem Pharmacol; 2012 May; 83(9):1278-89. PubMed ID: 22342732
[TBL] [Abstract][Full Text] [Related]
4. [Preliminary study of dihydroartemisin in inhibiting invasion and metastasis of hepatoma cells].
Feng BM; Han XL; Li YT; Yuan LX; Sun YC; Tang L
Zhongguo Zhong Yao Za Zhi; 2020 Feb; 45(3):683-688. PubMed ID: 32237529
[TBL] [Abstract][Full Text] [Related]
5. Semi-synthetic product dihydroartemisinin inhibited fibronectin-1 and integrin-β1 and interfered with the migration of HCCLM6 cells via PI3K-AKT pathway.
Wu R; Gao Y; Wu J; Wang C; Yang L
Biotechnol Lett; 2020 Jun; 42(6):917-926. PubMed ID: 32072334
[TBL] [Abstract][Full Text] [Related]
6. Dihydroartemisinin Sensitizes Mutant p53 (R248Q)-Expressing Hepatocellular Carcinoma Cells to Doxorubicin by Inhibiting P-gp Expression.
Yang Y; He J; Chen J; Lin L; Liu Y; Zhou C; Su Y; Wei H
Biomed Res Int; 2019; 2019():8207056. PubMed ID: 31976328
[TBL] [Abstract][Full Text] [Related]
7. Artemisinin inhibits in vitro and in vivo invasion and metastasis of human hepatocellular carcinoma cells.
Weifeng T; Feng S; Xiangji L; Changqing S; Zhiquan Q; Huazhong Z; Peining Y; Yong Y; Mengchao W; Xiaoqing J; Wan-Yee L
Phytomedicine; 2011 Jan; 18(2-3):158-62. PubMed ID: 20739158
[TBL] [Abstract][Full Text] [Related]
8. Dihydroartemisinin inhibited the Warburg effect through YAP1/SLC2A1 pathway in hepatocellular carcinoma.
Peng Q; Hao L; Guo Y; Zhang Z; Ji J; Xue Y; Liu Y; Li C; Lu J; Shi X
J Nat Med; 2023 Jan; 77(1):28-40. PubMed ID: 36068393
[TBL] [Abstract][Full Text] [Related]
9. Dihydroartemisinin induces apoptosis preferentially via a Bim-mediated intrinsic pathway in hepatocarcinoma cells.
Qin G; Zhao C; Zhang L; Liu H; Quan Y; Chai L; Wu S; Wang X; Chen T
Apoptosis; 2015 Aug; 20(8):1072-86. PubMed ID: 25935454
[TBL] [Abstract][Full Text] [Related]
10. Dihydroartemisinin, an antimalarial drug, induces absent in melanoma 2 inflammasome activation and autophagy in human hepatocellular carcinoma HepG2215 cells.
Shi X; Wang L; Ren L; Li J; Li S; Cui Q; Li S
Phytother Res; 2019 May; 33(5):1413-1425. PubMed ID: 30873702
[TBL] [Abstract][Full Text] [Related]
11. Systems Pharmacology-Based Identification of Mechanisms of Action of Bolbostemma paniculatum for the Treatment of Hepatocellular Carcinoma.
Wang LL; Liao C; Li XQ; Dai R; Ren QW; Shi HL; Wang XP; Feng XS; Chao X
Med Sci Monit; 2021 Jan; 27():e927624. PubMed ID: 33436534
[TBL] [Abstract][Full Text] [Related]
12. Study on the anti-tumor mechanism related to immune microenvironment of Bombyx Batryticatus on viral and non-viral infections of hepatocellular carcinoma.
Yuan L; Bing Z; Han J; An X; Liu X; Li R; Wang C; Sun X; Yang L; Yang K
Biomed Pharmacother; 2020 Apr; 124():109838. PubMed ID: 31981943
[TBL] [Abstract][Full Text] [Related]
13. Artesunate as an Anti-Cancer Agent Targets Stat-3 and Favorably Suppresses Hepatocellular Carcinoma.
Ilamathi M; Santhosh S; Sivaramakrishnan V
Curr Top Med Chem; 2016; 16(22):2453-63. PubMed ID: 26873192
[TBL] [Abstract][Full Text] [Related]
14. Dihydroartemisinin induced caspase-dependent apoptosis through inhibiting the specificity protein 1 pathway in hepatocellular carcinoma SK-Hep-1 cells.
Im E; Yeo C; Lee HJ; Lee EO
Life Sci; 2018 Jan; 192():286-292. PubMed ID: 29128513
[TBL] [Abstract][Full Text] [Related]
15. Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action.
Hou J; Wang D; Zhang R; Wang H
Clin Cancer Res; 2008 Sep; 14(17):5519-30. PubMed ID: 18765544
[TBL] [Abstract][Full Text] [Related]
16. [Current advances in molecular targeted therapy of primary hepatocellular carcinoma].
Yu L; Dai Z; Zhou J; Fan J
Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):475-7. PubMed ID: 19567036
[No Abstract] [Full Text] [Related]
17. Supramolecular hybrids of carbon dots and dihydroartemisinin for enhanced anticancer activity and mechanism analysis.
Li Y; Shi N; Zhang W; Zhang H; Song Y; Zhu W; Feng X
J Mater Chem B; 2020 Nov; 8(42):9777-9784. PubMed ID: 33026041
[TBL] [Abstract][Full Text] [Related]
18. Low-density lipoprotein docosahexaenoic acid nanoparticles induce ferroptotic cell death in hepatocellular carcinoma.
Ou W; Mulik RS; Anwar A; McDonald JG; He X; Corbin IR
Free Radic Biol Med; 2017 Nov; 112():597-607. PubMed ID: 28893626
[TBL] [Abstract][Full Text] [Related]
19. The anti-metastatic effect of 8-MOP on hepatocellular carcinoma is potentiated by the down-regulation of bHLH transcription factor DEC1.
Xiong J; Yang H; Luo W; Shan E; Liu J; Zhang F; Xi T; Yang J
Pharmacol Res; 2016 Mar; 105():121-33. PubMed ID: 26808085
[TBL] [Abstract][Full Text] [Related]
20. Melittin induces PTCH1 expression by down-regulating MeCP2 in human hepatocellular carcinoma SMMC-7721 cells.
Wu X; Zhao B; Cheng Y; Yang Y; Huang C; Meng X; Wu B; Zhang L; Lv X; Li J
Toxicol Appl Pharmacol; 2015 Oct; 288(1):74-83. PubMed ID: 26189965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
